Viral Hepatitis Flashcards
Hepatitis A is more symptomatic / severe in
A. Adults
B. Children
Adults
Only hepatitis virus with a DNA genome
HBV
Is the most frequent indication for liver transplant
CLD from HCV
Chronic liver disease from HCV
Defective virus that requires helper function of HBV for replication and expression
HDV
Usually from contaminated water supply after monsoon flooding in endemic areas
HEV
Tx for HDV
Interferon
Tx for HAV and HEV
None
Tx for HBV
Entecavir Tenofovir Adefovir Interferon PEG-IFN Lamivudine Telbivudine
HCV tx
PEG-IFN + Ribavirin
DAAs (direct acting antiviral agents):
Daclatasvir, Sofobuvir, Telaprevir, Boceprevir
Prophylaxis for HAV
Immunoglobulin
Inactivated vaccine
Prophylaxis HBV
HB-Ig
Recombinant vaccine
Prophylaxis for HCV
None
Prophylaxis for HDV
HBV recombinant vaccine
HEV prophylaxis
Vaccine
Prognosis
HAV
Excellent
Prognosis
HBV
Variable
Prognosis
HCV
Moderate
Prognosis
HDV
Variable
Prognosis
HEV
Good
Will not progress to chronicity
HAV, HEV
Commonly progresses to chronic hepatitis
HDV, HCV
Progression to chronicity HBV
Occasional, common if perinatal
Severity
HAV
Mild
Severity
HBV
Occasionally severe
Severity
HCV
Moderate
Severity
HDV
Occasionally severe
Severity
HEV
Mild
Predominant modes of transmission
HAV
Fecal-oral
Predominant modes of transmission
HBV
Percutaneous, perinatal, sexual
Predominant modes of transmission
HCV
Percutaneous
Predominant modes of transmission
HDV
Percutaneous, sexual
Predominant modes of transmission
HEV
Fecal-oral
Onset
HAV
Acute
Onset
HBV
Insidious or acute
Onset
HCV
Insidious
Onset
HDV
Insidious or acute
Onset
HEV
Acute
Prodromal symptoms
Anorexia Nausea and vomiting Fatigue Malaise Arthralgias Myalgias Headache Photophobia Pharyngitis Cough Coryza
Prodromal symptoms may precede onset of jaundice by
1-2 weeks
With the onset of jaundice the prodromal symptoms
A. Becomes severe
B. Diminish
Diminish
Complete clinical and biochemical recovery occurs after
1-2 months - hepatitis A and hepatitis E
3-4 months -after onset of jaundice hepatitis B and hepatitis C
Among health adults, acute hepatitis B is self-limited in
95-99%
Among health adults, acute hepatitis C is self-limited in
15%
AST and ALT increase during this phase of acute viral hepatitis preceding the rise in bilirubin level
Prodromal phase
Symptoms and signs of viral hepatitis
Phases
Prodromal
Jaundice
Recovery phase
Peak levels of aminotransferases vary from
400-4000 IU or more
Is hypoalbuminemia common in viral hepatitis
No.
it is uncommon in uncomplicated viral hepatitis
Lab results requested for viral hepatitis
Liver function test AST, ALT Bilirubin PT prothrombin time Alkaline phosphatase Serum albumin
HBsAg
IgM Anti-HAV
IgM Anti-HBc
Anti-HCV
(+) HBsAg
(-) IgM Anti-HAV
(+) IgM Anti-HBc
(-) Anti-HCV
Acute hepatitis B
(+) HBsAg
(+) IgM Anti-HAV
(-) IgM Anti-HBc
(-) Anti-HCV
Acute hepatitis A superimposed on chronic hepatitis B
(+) HBsAg
(+) IgM Anti-HAV
(+) IgM Anti-HBc
(-) Anti-HCV
Acute hepatitis A and B
(-) HBsAg
(-) IgM Anti-HAV
(-) IgM Anti-HBc
(+) Anti-HCV
Hepatitis C
HBsAg
(+) IgM Anti-HAV
IgM Anti-HBc
Anti-HCV
Acute hepatitis A
Sequelae of acute viral hepatitis
Fulminant hepatitis
progression to chronic liver disease
Most feared complication of viral hepatitis
Fulminant hepatitis
Fulminant hepatitis is primarily seen in
Hepatitis A, B, D, E
Fulminant hepatitis
Clinical manifestations
Signs and symptoms of encephalopathy that may evolve into deep coma
Terminal events of fulminant hepatitis
Brainstem compression GI bleeding Sepsis Respiratory failure Cardiovascular collapse Renal failure
Massive hepatic necrosis
Fulminant hepatitis
When will chronic hepatitis E occur
In immunocompromised patients
Criteria to diagnose chronic hepatitis B
Persistence of HBeAg for >3 months or
HBsAg > 6 months
For acute HCV infection, the likelihood of remaining chronically infected approaches ___%
90%
(+) HBsAG (-) Anti-HBS (+) IgM Anti-HBc (+) HBeAg (-) Anti-HBe
Acute Hepatitis B , high-infectivity
(+) HBsAG (-) Anti-HBS (+) IgG Anti-HBc (+) HBeAg (-) Anti-HBe
Chronic Hepatitis B, high infectivity
(-) HBsAG (-) Anti-HBS (+) IgM Anti-HBc (+/-) HBeAg (+/-) Anti-HBe
Anti-HBC “window”
(-) HBsAG (-) Anti-HBS (+) IgG Anti-HBc (-) HBeAg (+/-) Anti-HBe
Hepatitis B in remote past
(-) HBsAG (+) Anti-HBS (+) IgG Anti-HBc (-) HBeAg (+/-) Anti-HBe
Recovery from Hepatitis B
(-) HBsAG (+) Anti-HBS (-) IgM Anti-HBc (-) HBeAg (-) Anti-HBe
Immunization with HBsAg
Sequelae of Chronic Viral Hepatitis
Liver cirrhosis Hepatocellular carcinoma (Hepatitis B & C), esp if Hepatitis B is acquired perinatally
Will treatment with antivirals decrease risk of HCC
Yes. But will not eliminate it
Surveillance for HCC should continue even after treatment
HCC is mainly associated with
Hep B and C
Factors that affect decision to treat and or Duration of treatment for Hepatitis B
Clinical status (presence of cirrhosis, compensated vs decompensated, liver mass/ hepatocellular carcinoma) Fam Hx of hepatocellular carcinoma HBeAg status HBV DNA titers ALT levels
Factors that affect decision to treat and or Duration of treatment for Hepatitis C
Detectable HCV RNA in serum
HCV genotype
Presence of significant fibrosis , cirrhosis
Treatment for HBV (with doses)
High genetic barrier to resistance drugs
- Entecavir 0.5 mg PO OD, Tenofovir 300 mg PO OD)
- Pegylated Interferon once weekly SC injection
- Lamivudine 100 gm PO OD - first successful oral antiviral agent ; no longer recommended as first line except in short-term therapy such as cancer chemotherapy
Treatment Hepatitis C (detailed)
DAAS: Daclatasvir, Sofobuvir, Telaprevir, Boceprevir, Dasabuvir, Ledipasvir
Pegylated Interferon + Ribavirin
a. Genotype 1 : 48 weeks
B. Genotype 2 : 24 weeks
Most pronounced side effectof ribavirin is
Hemoylsis
Diagnostic test for Acute Hep B infection
HBsAg
IGM Anti-HBc
Chronic Hep B infection
HBsAg
IgG anti-HBc
Markers of Hepatitis B replication
HBeAg
HBV DNA
Hepatitis C
Diagnostic Test
Anti-HCV
HCV RNA
Hepatitis D
Diagnostic test
HBsAg, anti-HDV
HBV/HDV coinfection
Diagnostic test
IgM anti-HBc
IgM Anti-HDV
HDV superinfection
IgG anti-HBc
IgM anti-HDV
Hepatitis E infection
Diagnostics
Anti-HEV
Diagnosis of Hepatitis A during acute illness and persists for several months
Anti-HAV (IgM)
Detected when aminotransferase activity is elevated and fecal HAV shedding is still occuring
After acute illness fo HAV, remains detectable indefinitely
anti-HAV (IgG)
Predominates during convalescence of HAV
Marker of IMMUNITY to reinfection
Anti-HAV (IgG)
First virologic marker detectable in the serum within 1 -12 weeks after infection with HBV
HBsAg
After HBsAg disappears, this becomes detectable and remains detectable indefinitely thereafter (protective antibody)
Anti-HBs
The only serologic marker that appears after vaccination with HBV recombinant vaccine
Anti-HBs
IgM anti-HBc predominates during the ____ months after acute infection
1st 6 months and anti-HBc window period
Predominates the class of anti-HBc 6 months after acute infection
IgG anti-HBc
An isolated reactive anti-HBc can be seen in
Gap or window period of acute Hepatitis B
Occult infection
Remote infection
False positive
Appears concurrently with shortly after HBsAg
HBeAg
Qualitative marker of HBV replication and relative infectivity
HBeAg
Its diappearance may be a harbinger of clinical improvement and resolution of infection of Hepatitis B
HBeAg
Its appearance coincides with a period of relatively lower infectivity
Anti-HBeq
More sensitive and quantitative indicator of HBV replication
HBV DNA
Diagnosis of hepatitis C
Anti-HCV
Most sensitive test for HCV infection
Gold standard for diagnosis of HCV
HCV RNA
Testing for anti-HDV is useful in those with hepatitis B and severe/ fulminant disease
Anti-HDV